OXGR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL26264600	1.00	3/20
SCHEMBL26265025	1.00	3/20
SCHEMBL26266523	1.00	3/20
SCHEMBL26265026	0.79	3/20
SCHEMBL26263389	0.79	3/20
SCHEMBL26263641	0.77	3/20
SCHEMBL26263391	0.73	3/20
SCHEMBL26264556	0.68	3/20
SCHEMBL26265075	0.64	3/20
SCHEMBL26264776	0.55	3/20
SCHEMBL26269260	0.54	3/20
SCHEMBL26266669	0.52	3/20
SCHEMBL26264601	0.51	3/20
SCHEMBL26264961	0.51	3/20
SCHEMBL26267111	0.51	3/20
SCHEMBL26264929	0.50	3/20
SCHEMBL26265104	0.50	3/20
SCHEMBL26263398	0.49	3/20
SCHEMBL26263638	0.46	3/20
SCHEMBL26263399	0.46	3/20

Clinical trials — most relevant to OXGR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype	PHASE2	ACTIVE_NOT_RECRUITING
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy	PHASE2	SUSPENDED
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Erythropoietin Therapy for Subarachnoid Hemorrhage	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer	PHASE2	COMPLETED
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors	PHASE2	ACTIVE_NOT_RECRUITING
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study	PHASE1/PHASE2	COMPLETED
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Endometriosis and Microvascular Dysfunction: Role of Inflammation	EARLY_PHASE1	RECRUITING
Changes in Glutamatergic Neurotransmission of Severe TBI Patients	EARLY_PHASE1	SUSPENDED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery	nan	COMPLETED
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas	nan	COMPLETED
Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma	nan	NOT_YET_RECRUITING
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy	nan	UNKNOWN
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus	nan	COMPLETED
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients	nan	COMPLETED
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features	nan	UNKNOWN
Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study	nan	COMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
Association Between the Change of the Genes With Hormones and Food Consumption of Obese	nan	COMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl	nan	COMPLETED
Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a OXGR1 binder may also engage these)

Protein	Name	Similarity
Q6IYF8	—	1.000	Q6IYF8 →
Q6Y1R5	—	1.000	Q6Y1R5 →
P49652	—	0.992	P49652 →
P59902	—	0.990	P59902 →
P48042	—	0.990	P48042 →
Q99MT6	—	0.990	Q99MT6 →
P49650	—	0.988	P49650 →
P34996	—	0.988	P34996 →
Q6IYF9	—	0.988	Q6IYF9 →
Q924T8	—	0.988	Q924T8 →
P49651	—	0.987	P49651 →
Q924T9	—	0.986	Q924T9 →
P2RY1	P2Y purinoceptor 1	0.985	landscape →
Q920A1	—	0.984	Q920A1 →
SUCNR1	Succinate receptor 1	0.984	landscape →
GPR174	Probable G-protein coupled receptor 174	0.983	landscape →
CYSLTR2	Cysteinyl leukotriene receptor 2	0.983	landscape →
Q3U507	—	0.983	Q3U507 →
Q95N02	—	0.983	Q95N02 →
Q5ZI82	—	0.983	Q5ZI82 →
Q920E1	—	0.982	Q920E1 →
D4A7K7	—	0.981	D4A7K7 →
Q2NNR5	—	0.980	Q2NNR5 →
Q95N03	—	0.978	Q95N03 →
Q99JA4	—	0.978	Q99JA4 →
CYSLTR1	Cysteinyl leukotriene receptor 1	0.978	landscape →
Q2Y2P0	—	0.977	Q2Y2P0 →
B5X337	—	0.977	B5X337 →
Q9ESG6	—	0.977	Q9ESG6 →
P2RY10	Putative P2Y purinoceptor 10	0.977	landscape →